Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells / SZGIMI
NCT04010877: Multiple CAR-T Cell Therapy Targeting AML	Recruiting	1/2	10	RoW	CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells	Shenzhen Geno-Immune Medical Institute	Acute Myeloid Leukemia	07/21	12/23